231 related articles for article (PubMed ID: 29288421)
1. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
Castelli R; Bergamaschini L; Deliliers GL
Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
[TBL] [Abstract][Full Text] [Related]
3. Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.
Morigi A; Argnani L; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Casadei B; Sabattini E; Cavo M; Zinzani PL
Hematol Oncol; 2020 Oct; 38(4):487-492. PubMed ID: 32594531
[TBL] [Abstract][Full Text] [Related]
4. How to treat splenic marginal zone lymphoma (SMZL) in patients unfit for surgery or more aggressive therapies: experience in 30 cases.
Cervetti G; Ghio F; Cecconi N; Morganti R; Galimberti S; Petrini M
J Chemother; 2017 Apr; 29(2):126-129. PubMed ID: 27454143
[TBL] [Abstract][Full Text] [Related]
5. Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine.
Scapinello G; Pizzi M; Vio S; Nabergoj M; Visentin A; Martines A; Bonaldi L; Trentin L; Semenzato G; Piazza F
Ann Hematol; 2018 Oct; 97(10):2001-2003. PubMed ID: 29728736
[No Abstract] [Full Text] [Related]
6. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJG; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Hematology; 2017 Aug; 22(7):405-411. PubMed ID: 28105889
[TBL] [Abstract][Full Text] [Related]
7. Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era.
Perrone S; D'Elia GM; Annechini G; Ferretti A; Tosti ME; Foà R; Pulsoni A
Leuk Res; 2016 May; 44():53-60. PubMed ID: 27030961
[TBL] [Abstract][Full Text] [Related]
8. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
Cervetti G; Galimberti S; Pelosini M; Ghio F; Cecconi N; Petrini M
Ann Oncol; 2013 Sep; 24(9):2434-8. PubMed ID: 23712547
[TBL] [Abstract][Full Text] [Related]
9. Risk-tailored treatment of splenic marginal zone lymphoma.
Castelli R; Balzarotti M; Salvi E; Simona Rossi R; Lambertenghi Deliliers G; Bergamaschini L; Gidaro A
Anticancer Drugs; 2022 Jan; 33(1):e36-e42. PubMed ID: 34407041
[TBL] [Abstract][Full Text] [Related]
10. Splenic marginal zone lymphoma: from genetics to management.
Arcaini L; Rossi D; Paulli M
Blood; 2016 Apr; 127(17):2072-81. PubMed ID: 26989207
[TBL] [Abstract][Full Text] [Related]
11. The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.
Laribi K; Tempescul A; Ghnaya H; Denizon N; Besançon A; Anghel A; Farhi J; Truong C; Lemaire P; Poulain S; Bolle D; Ianotto JC; Baugier de Materre A
Hematol Oncol; 2017 Dec; 35(4):536-541. PubMed ID: 27443419
[TBL] [Abstract][Full Text] [Related]
12. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles.
Arcaini L; Paulli M; Boveri E; Vallisa D; Bernuzzi P; Orlandi E; Incardona P; Brusamolino E; Passamonti F; Burcheri S; Schena C; Pascutto C; Cavanna L; Magrini U; Lazzarino M
Cancer; 2004 Jan; 100(1):107-15. PubMed ID: 14692030
[TBL] [Abstract][Full Text] [Related]
13. Results of Upfront Therapy for Marginal Zone Lymphoma.
Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
[TBL] [Abstract][Full Text] [Related]
14. Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life.
Mulas O; Caocci G; Dessì D; Mantovani D; Moi G; Cabras MG; La Nasa G
Acta Haematol; 2021; 144(3):322-326. PubMed ID: 32892194
[TBL] [Abstract][Full Text] [Related]
15. Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center.
de Pádua Covas Lage LA; Dos Santos FFC; Levy D; Moreira FR; Couto SCF; Culler HF; de Oliveira Costa R; Rocha V; Pereira J
BMC Cancer; 2020 Aug; 20(1):717. PubMed ID: 32746790
[TBL] [Abstract][Full Text] [Related]
16. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
[TBL] [Abstract][Full Text] [Related]
17. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma.
Olszewski AJ; Ali S
Ann Hematol; 2014 Mar; 93(3):449-58. PubMed ID: 24057925
[TBL] [Abstract][Full Text] [Related]
18. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
Bennett M; Schechter GP
Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
[TBL] [Abstract][Full Text] [Related]
20. Rare presentation of secondary cutaneous involvement by splenic marginal zone lymphoma: report of a case and review of the literature.
Cohen JM; Nazarian RM; Ferry JA; Takvorian RW; Carter JB
Am J Dermatopathol; 2015 Jan; 37(1):e1-4. PubMed ID: 25238446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
